Acquired partial lipodystrophy
uh-kwai-erd par-shuhl lip-oh-dis-troh-fee
Also known as: Barraquer-Simons Syndrome, Progressive Lipodystrophy
At a Glance
What is Acquired partial lipodystrophy?
Acquired partial lipodystrophy is a rare condition where individuals lose fat from specific areas of the body, typically the face and upper body. This condition affects the metabolic and immune systems, leading to complications like insulin resistance and autoimmune disorders. It is believed to be caused by an abnormal immune response that targets fat cells. Over time, the loss of fat can lead to noticeable changes in appearance and metabolic health. Early symptoms include facial fat loss, while later stages may involve metabolic issues like diabetes. Early diagnosis is crucial to manage symptoms and prevent complications. The condition can impact family life due to the need for ongoing medical care and lifestyle adjustments. Prognosis varies, but with proper management, individuals can lead relatively normal lives. Daily life may involve regular medical check-ups, dietary adjustments, and monitoring for associated health issues. Support from healthcare professionals and family is essential for managing the condition. Psychological support may also be beneficial due to changes in appearance. Overall, maintaining a healthy lifestyle is key to managing acquired partial lipodystrophy.
Medical Definition
Acquired partial lipodystrophy is characterized by the progressive loss of subcutaneous fat, primarily affecting the face and upper body. Pathologically, it involves the dysregulation of the complement system, often linked to C3 glomerulopathy. Histological findings may show a reduction in adipose tissue without significant inflammation. It is classified under lipodystrophy syndromes and is considered a rare disease with an estimated prevalence of 1 in 1,000,000. The disease course is progressive, with fat loss typically beginning in childhood or early adulthood. Management focuses on addressing metabolic complications and monitoring for autoimmune conditions.
Acquired partial lipodystrophy Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
This symptom manifests as a noticeable reduction in fat tissue, primarily in the face, arms, and upper body. The biological mechanism involves immune-mediated destruction of adipocytes, often linked to complement system dysregulation. Over time, the fat loss can progress to other areas, leading to a more generalized appearance of emaciation. This affects daily life by altering physical appearance, potentially leading to psychological distress, and management includes cosmetic interventions and psychological support.
Clinically, insulin resistance presents as elevated blood glucose levels despite normal or high insulin production. It is caused by the body's inability to effectively use insulin, often due to changes in fat distribution affecting insulin signaling pathways. Over time, this can progress to type 2 diabetes if not managed. It impacts daily life by necessitating dietary changes and regular monitoring of blood sugar levels, with management strategies including lifestyle modifications and medications like metformin.
Hypertriglyceridemia is characterized by elevated levels of triglycerides in the blood. This occurs due to impaired lipid metabolism, often as a consequence of altered fat distribution and insulin resistance. If left unchecked, it can lead to pancreatitis and increase cardiovascular risk over time. Management involves dietary modifications, physical activity, and possibly lipid-lowering medications to mitigate these risks.
Common
C3 glomerulopathy presents with proteinuria and hematuria, indicating kidney involvement. It results from complement system dysregulation leading to kidney inflammation and damage. Over time, this can progress to chronic kidney disease if not addressed. Daily life is affected by the need for regular kidney function monitoring and management may include immunosuppressive therapy to control the underlying immune process.
Patients may develop autoimmune diseases such as autoimmune hepatitis, presenting with fatigue, jaundice, and elevated liver enzymes. The mechanism involves the immune system mistakenly attacking the body's own tissues. These conditions can progress to significant organ damage if untreated. Management includes immunosuppressive medications and regular monitoring to prevent complications.
Metabolic syndrome is characterized by a cluster of conditions including hypertension, dyslipidemia, and central obesity. It arises due to insulin resistance and altered lipid metabolism associated with fat redistribution. Over time, it increases the risk for cardiovascular diseases and type 2 diabetes. Lifestyle interventions and medications are used to manage these risks and improve patient outcomes.
Less Common
Hepatomegaly is the enlargement of the liver, which may be detected during a physical examination. It can occur due to fat accumulation in the liver, known as hepatic steatosis, secondary to metabolic disturbances. Over time, this can lead to liver dysfunction or non-alcoholic fatty liver disease. Management involves addressing the underlying metabolic issues through lifestyle changes and monitoring liver function regularly.
Fatigue is a common, non-specific symptom that presents as persistent tiredness and lack of energy. It may be related to metabolic imbalances, autoimmune activity, or psychological stress associated with the condition. Over time, chronic fatigue can significantly impair quality of life and daily functioning. Management includes addressing underlying causes, ensuring adequate nutrition, and incorporating rest and stress management techniques.
What Causes Acquired partial lipodystrophy?
Acquired partial lipodystrophy, also known as Barraquer-Simons syndrome, is primarily associated with dysregulation of the complement system, particularly involving the C3 convertase. The CFH gene, located on chromosome 1q32, encodes complement factor H, a regulatory protein that controls the alternative pathway of complement activation. Mutations or autoantibodies affecting complement factor H lead to uncontrolled complement activation, resulting in excessive consumption of complement component C3. This dysregulation causes a reduction in serum C3 levels and deposition of complement components in tissues, particularly affecting adipose tissue. The loss of adipose tissue is thought to be due to complement-mediated damage, where adipocytes are targeted and destroyed. This process can trigger an inflammatory response, recruiting immune cells that exacerbate tissue damage. Neuroinflammation may occur due to systemic immune activation, potentially affecting neural tissues indirectly. The degeneration of adipose tissue follows a cephalocaudal pattern, beginning in the face and progressing downward, which is characteristic of this condition. The variability in disease severity among patients may be influenced by genetic factors, the presence of autoantibodies, and environmental triggers. Some patients may develop associated conditions like C3 glomerulopathy, indicating renal involvement due to complement deposition. The immune response may also contribute to the development of autoimmune conditions in some individuals, further complicating the clinical picture. The interplay between genetic predisposition and immune dysregulation is crucial in understanding the phenotypic variability. While the primary defect lies in the complement system, secondary effects on metabolic pathways can lead to insulin resistance and dyslipidemia. Understanding the molecular basis of this condition is essential for developing targeted therapies that can modulate complement activity and prevent tissue damage.
How is Acquired partial lipodystrophy Diagnosed?
Typical age of diagnosis: Acquired partial lipodystrophy is typically diagnosed in childhood or early adulthood, often following a noticeable loss of subcutaneous fat in the upper body. Diagnosis usually occurs after patients or their families observe changes in body fat distribution, prompting medical evaluation. The condition may be identified during assessments for associated metabolic or autoimmune disorders. Early recognition is crucial for managing potential complications and initiating appropriate treatment.
Clinicians look for a characteristic loss of subcutaneous fat in the face, neck, arms, and trunk, sparing the lower body. A detailed history is taken to identify any preceding infections or autoimmune conditions. Physical examination reveals fat loss and may include signs of metabolic derangements like insulin resistance. This step helps differentiate acquired partial lipodystrophy from other forms of lipodystrophy and guides further diagnostic testing.
Magnetic resonance imaging (MRI) is commonly used to assess fat distribution and confirm the diagnosis. MRI reveals a distinct pattern of fat loss in the upper body with preservation in the lower body. These findings support the diagnosis of acquired partial lipodystrophy and help exclude other conditions such as congenital lipodystrophy. Imaging also aids in identifying any associated organ involvement or complications.
Specific tests include serum complement levels, particularly C3 and C4, and autoantibody panels. Biomarkers such as low C3 levels and the presence of complement factor H autoantibodies are sought. Abnormal results, like reduced complement levels, indicate complement system dysregulation. These results guide further investigation into associated conditions like C3 glomerulopathy and inform treatment decisions.
Although acquired partial lipodystrophy is not primarily genetic, testing may include sequencing of genes related to complement regulation. Mutations in genes like CFH or CFI may be found, indicating a genetic predisposition to complement dysregulation. Results confirm the diagnosis and help differentiate from hereditary lipodystrophies. Genetic findings also inform family counseling regarding the risk of related conditions.
Acquired partial lipodystrophy Treatment Options
Immunosuppressants such as corticosteroids or mycophenolate mofetil are used to manage autoimmune components. These drugs work by reducing immune system activity and inflammation. Specific drugs like prednisone have shown efficacy in controlling disease progression. Clinical evidence supports their use in reducing complement-mediated damage, but side effects include increased infection risk and metabolic disturbances. Long-term use requires careful monitoring and dose adjustments.
Exercise therapy involves tailored physical activity programs to improve metabolic health and muscle strength. The goal is to enhance insulin sensitivity and overall physical fitness. Sessions are typically conducted 2-3 times per week, lasting 30-60 minutes each. Measurable outcomes include improved glucose tolerance and increased muscle mass. Long-term benefits include reduced cardiovascular risk and improved quality of life.
Liposuction may be indicated for cosmetic reasons or to alleviate physical discomfort due to fat redistribution. The procedure involves the removal of excess fat from areas where it accumulates, such as the lower body. Expected benefits include improved body contour and patient self-esteem. Surgical risks include infection, scarring, and asymmetry. Post-operative care requires monitoring for complications and gradual return to normal activities.
A multidisciplinary team typically includes endocrinologists, dietitians, and mental health professionals. Interventions focus on metabolic control, nutritional support, and psychological well-being. Psychosocial support strategies involve counseling and support groups for patients and families. Family education covers disease management and lifestyle modifications. Long-term monitoring includes regular follow-ups to assess treatment efficacy and adjust care plans as needed.
When to See a Doctor for Acquired partial lipodystrophy
- Severe abdominal pain — this could indicate acute pancreatitis, a potentially life-threatening condition requiring immediate medical attention.
- Sudden onset of confusion or altered mental status — this may suggest severe metabolic derangement or neurological involvement.
- Rapid swelling of the face or extremities — could indicate angioedema or severe allergic reaction, necessitating emergency care.
- Persistent fatigue — may indicate metabolic complications or anemia, and should be evaluated by a healthcare provider.
- Unexplained weight loss — could signify worsening metabolic imbalance or underlying disease progression, warranting medical assessment.
- New skin changes or rashes — might suggest autoimmune activity or infection, and should be discussed with a doctor.
- Mild joint pain — monitor for worsening symptoms and consider over-the-counter pain relief; consult a doctor if it persists.
- Occasional headaches — track frequency and severity; if they increase or become debilitating, seek medical advice.
Acquired partial lipodystrophy — Frequently Asked Questions
Is this condition hereditary?
Acquired partial lipodystrophy is not typically hereditary, as it is acquired rather than inherited. The condition usually arises due to autoimmune or environmental factors rather than genetic mutations. De novo mutations are not a common cause of this condition. Carrier status is not applicable as it is not passed from parent to child. Genetic counseling is generally not necessary for this condition, but may be helpful in understanding related autoimmune disorders.
What is the life expectancy for someone with this condition?
Life expectancy can vary depending on the age of onset and the presence of associated complications. Early diagnosis and management of metabolic and autoimmune complications can improve outcomes. Mortality is often related to complications such as renal disease or cardiovascular issues. Effective treatment of metabolic derangements can enhance survival and quality of life. Patients should have realistic expectations about managing chronic symptoms and potential complications.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, laboratory tests, and imaging studies. The time from first symptoms to diagnosis can vary, often taking several months. Specialists such as endocrinologists and nephrologists are typically involved in the diagnostic process. Delayed diagnosis may occur due to the rarity of the condition and overlapping symptoms with other disorders. Confirmation is usually achieved through clinical criteria and exclusion of other causes of lipodystrophy.
Are there any new treatments or clinical trials available?
Research is ongoing into the role of complement inhibitors and other immunomodulatory therapies. Gene therapy is not currently a focus, but novel approaches like monoclonal antibodies are being explored. ClinicalTrials.gov is a resource for finding relevant clinical trials. Patients should discuss potential trial participation with their healthcare provider. New treatments may become available in the next few years, but timelines are uncertain.
How does this condition affect daily life and activities?
Mobility and self-care can be affected by muscle weakness and fatigue. Educational performance may be impacted by cognitive difficulties or frequent medical appointments. Social and emotional challenges include coping with body image changes and potential isolation. Family members may experience increased caregiving responsibilities. Supportive therapies and adaptive equipment can help manage daily activities and improve quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Acquired Partial Lipodystrophy: Clinical Management in a Pregnant Patient.
Romanisio M, Bighetti L, Daffara T et al. · J Endocr Soc · 2024 · PMID: 39479521
- 2.Lipodystrophy Syndromes.
Hussain I, Garg A · Endocrinol Metab Clin North Am · 2016 · PMID: 27823605
- 3.Acquired partial lipodystrophy and C3 glomerulopathy: Dysregulation of the complement system as a common pathogenic mechanism.
Corvillo F, López-Trascasa M · Nefrologia (Engl Ed) · 2018 · PMID: 29279276
- 4.Acquired partial lipodystrophy with metabolic disease in children following hematopoietic stem cell transplantation: a report of two cases and a review of the literature.
Hosokawa M, Shibata H, Hosokawa T et al. · J Pediatr Endocrinol Metab · 2019 · PMID: 31075084
- 5.Autoimmune hepatitis and acquired partial lipodystrophy.
Bakewell C, Dayasiri K, Brown RM et al. · Frontline Gastroenterol · 2022 · PMID: 35300473
- 6.Clinical Characteristics of Patients With Acquired Partial Lipodystrophy: A Multicenter Retrospective Study.
Magno S, Ceccarini G, Corvillo F et al. · J Clin Endocrinol Metab · 2024 · PMID: 38061004
- 7.Lipodystrophies.
Garg A · Am J Med · 2000 · PMID: 11126308
- 8.Clinical Features, Metabolic and Autoimmune Derangements in Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome).
Kaewkrasaesin C, Hwang M, Vasandani C et al. · J Clin Endocrinol Metab · 2025 · PMID: 40435301
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-11